Specifically, as noted by Commissioner Ekaterina Zaharieva, the Commission is committed to setting up a new SCaleup Europe and expanding the European Innovation Council with the aim of enhancing innovative ideas throughout their life cycle.
In addition, the Commission, in coordination with the European Investment Bank, will work with large institutional investors to develop a European Investment Investment Pact in innovation aimed at investing part of the assets of these investors in developing new businesses, EU investment funds and investment funds and investment funds. start -up businesses on issues related to their mental property.
The committee highlights That will create a European ecosystem for clinical research with new actions, which will be included in the forthcoming strategy for bio -science and biotechnology practice, while noting that in 2023, it has begun cooperation with the National Cancer Institute of Cancer and Cancer Cancer and Cancer Cancer Cancer.
These actions are aimed at implementing the mission of the “Horizon Europe” program for cancer, which aims to improve the lives of more than 3 million people by 2030, through prevention and treatment, as well as to extend and improve the lives of people with cancer, including their families.
It is recalled that D. Tsiodras in his questionHe had pointed out that “despite the fact that the number of European startups operating in this sector is not significantly different from the number of US (1,027 starters in the EU for 1,325 in the US), US businesses are growing faster than their respective European.”
He had not requested a network of measures to strengthen start -up businesses so that Europe would remain at the forefront of world -class cancer research. “
Following the text of the Question of Tsiodra:
Question with a written response request to the committee
Theme: Strengthening European start -ups active in cancer technologies
In the EU, there are about 1,027 startups that are active in treatment of cancer (1,325 in the US) with 41.6% remaining in the early stage of growth, while 34.7% still stands in the starting stage[1].
On the contrary, US companies are growing faster, resulting in 40% of them being in a more advanced stage (compared to 24% in the EU) and hold significantly larger patent diploma portfolios (in technologies such as cellular immunotherapy, gene therapy and image analysis).
Businesses in the US have 82% more international patents than their respective EU, while starters and early businesses exceed EU portfolios by 58% and 56%, respectively.
The Commission is asked:
1. In what actions will it take for Europe to remain At the forefront of the world’s cancer research?
2. In view of the strategy for start -ups, how will it enhance access to funding and whether it is considering the creation of a European initiative to enhance institutional investors in Venture Capital?